Thymosin α1 to harness immunity to pathogens after haploidentical hematopoietic transplantation

Annals of the New York Academy of Sciences

Volumn 1194, Issue , 2010, Pages 153-161

  Perruccio, Katia ^a   Bonifazi, Pierluigi ^a   Topini, Fabiana ^a   Tosti, Antonella ^a   Bozza, Silvia ^a   Aloisi, Teresa ^a   Carotti, Alessandra ^a   Aversa, Franco ^a   Martelli, Massimo F ^a   Romani, Luigina ^a   Velardi, Andrea ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Haploidentical transplantation; Hematopoietic transplantation; Immune reconstitution; Thymosin 1; Transplant related mortality

Indexed keywords

THYMOSIN ALPHA1; DRUG DERIVATIVE; THYMOSIN;

ACUTE GRAFT VERSUS HOST DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; GRAFT RECIPIENT; HAPLOIDY; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; LUNG ASPERGILLOSIS; LYMPHOCYTE COUNT; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMORPHONUCLEAR CELL; T LYMPHOCYTE; ASPERGILLUS; BLOOD DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; IMMUNITY; IMMUNOLOGY; INFECTION; PATHOPHYSIOLOGY; REVIEW; SIMPLEXVIRUS;

ASPERGILLUS; CANDIDA; HARNESS; HUMAN HERPESVIRUS 3; SIMPLEXVIRUS; TOXOPLASMA;

ASPERGILLUS; DENDRITIC CELLS; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY; INFECTION; SIMPLEXVIRUS; T-LYMPHOCYTES; THYMOSIN;

EID: 77951865159     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05486.x     Document Type: Conference Paper

References (72)

1. Russell, N.H. & G. Miflin. 1998. Peripheral blood stem cells for autologous and allogeneic transplantation. In The Clinical Practice of Stem-Cell Transplantation, vol.1. John Barrett & Jennifer Treleaven. Eds.: 462.
2. Sociè, G. & J.-Y. Cahn. 1998. Acute graft-versus-host disease. In The Clinical Practice of Stem-Cell Transplantation, vol.2. John Barrett & Jennifer Treleaven, Eds.: 602.
3. Beatty, P.G. Clinical and managed care issues in blood and marrow transplantation for hematologic diseases. Exp. Hematol. 25: 1195-1208.
4. Thomas, E.D., C.D. Buckner, J.E. Sanders, et al. 1982. Marrow transplantation for thalassemia. Lancet 8292: 227-229.
5. Fischer,A., P. Landais,W. Friedrich, et al. 1990.European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet 336: 850-854.
6. Buckley, R.H., S.E. Schiff, R.I. Schiff, et al. 1999. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 340: 508-516.
7. Reisner, Y. & H. Segall. 1995. Hematopoietic stem cell transplantation for cancer therapy.Curr.Opin. Immunol. 5: 687-693.
8. Reisner, Y. & M.F. Martelli. 2002. Tolerance induction by "megadose" transplants of CD34+ stem cells: a new option for leukemia patients without an HLA-matched donor. Curr. Opin. Immunol. 12: 536-541.
9. Gluckman, E., H.A. Broxmeyer, A.D. Auerbach, et al. 1989. Hematopoietic reconstitution in a patient with Fanconi's anemia by means ofumbilical-cord blood from an HLA-identical sibling. N. Engl. J. Med. 321: 1174-1178.
10. Hansen, J.A., E. Petersdorf, P.J. Martin & C. Anasetti. 1997. Hematopoietic stem cell transplants from unrelated donors. Immunol. Rev. 157: 141-151.
11. Wagner, J.E., J.N. Barker, T.E. DeFor, et al. 2002. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100: 1611-1618.
12. Laughlin,M.J., M. Eapen, P. Rubinstein, et al. 2004. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N. Engl. J. Med. 351: 2265-2275.
13. Rocha, V., M. Labopin, G. Sanz, et al. 2004. Transplants of umbilical-cord blood or bone marrow fromunrelated donors in adults with acute leukemia. N. Engl. J. Med. 351: 2276-2285.
14. Barker, J.N.,D.J.Weisdorf, T.E.DeFor, et al. 2005. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adultswith hematologic malignancy. Blood 105: 1343-1347.
15. Aversa, F., A. Tabilio, A. Velardi, et al. 2007. Hematopoietic stem cell transplantation from alternative donors for high-risk leukemia: the haploidentical option. Curr. Stem Cell Res. Ther. 2: 105-112.
16. Anasetti,C.&A.Velardi. 2003.Hematopoietic cell transplantation from HLA partially matched related donors. In Hematopoietic Cell Transplantation. K. Blume, S. Forman & F. Appelbaum, Eds.: Blackwell Science. Malden.
17. Atkinson, K.,W. Fibbe, R. Champlin, et al. 2004. Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd edn. Cambridge University Press. Cambridge.
18. Copelan, E.A. 2006. Hematopoietic stem-cell transplantation. N. Engl. J. Med. 354: 1813-1826.
19. Beatty, P.G., M.Mori&E.Milford. 1995. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 60: 778-783.
20. Goulmy, E., R. Schipper, J. Pool, et al. 1996.Mismatches of minor histocompatibility antigens between HLAidentical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 334: 281-285.
21. Wang, W., L.R. Meadows, J.M. den Haan, et al. 1995. Human H-Y: a male-specific histocompatibility antigen derived fromtheSMCYprotein. Science 269: 1588-1590.
22. Goulmy, E. 1997.Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol. Rev. 157: 125-140.
23. Mutis, T. & E. Goulmy. 2002. Hematopoietic systemspecific antigens as targets for cellular immunotherapy of hematological malignancies. Semin. Hematol. 39: 23-31.
24. Spierings, E. & E. Goulmy. 2005. Expanding the immunotherapeutic potential of minor histocompatibility antigens. J. Clin. Invest. 115: 3397-3400. (Pubitemid 43121825)
25. Reisner, Y.,N. Kapoor,D. Kirkpatrick, et al. 1983. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DRincompatible parentalmarrowcells fractionatedby soybeanagglutininandsheep redbloodcells. Blood 61: 341-348.
26. Bachar-Lustig, E., N. Rachamim, H.W. Li, et al. 1995. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat. Med. 1: 1268-1273.
27. Aversa, F., A. Tabilio, A. Terenzi, et al. 1994. Successful engraftment of T-cell-depleted haploidentical "threeloci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colonystimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84: 3948-3955.
28. Aversa, F., A. Tabilio, A. Velardi, et al. 1998. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 339: 1186-1193.
29. Aversa, F., A. Velardi, A. Tabilio, et al. 2001.Haploidentical stem cell transplantation in leukemia. Blood Rev. 15: 111-119.
30. Martelli, M.F., F. Aversa, E. Bachar-Lustig, et al. 2002. Transplants across human leukocyte antigen barriers. Semin. Hematol. 39: 48-56.
31. Aversa, F., A. Terenzi, A. Tabilio, et al. 2005. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J. Clin. Oncol. 23: 3447-3454.
32. Ruggeri, L., M. Capanni, E. Urbani, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
33. Farag, S.S., T.A. Fehniger, L. Ruggeri, et al. 2002.Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100: 1935-1947.
34. Velardi, A., L. Ruggeri, A. Moretta & L. Moretta. 2002. NKcells: a lesson frommismatched hematopoietic transplantation. Trends Immunol. 23: 438-444.
35. Ruggeri, L., F. Aversa, M.F. Martelli & A. Velardi. 2006. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol. Rev. 214: 202-218. (Pubitemid 44707912)
36. Ruggeri, L., M. Capanni, M. Casucci, et al. 1999. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94: 333-339.
37. Karre, K. 2002. Immunology. A perfect mismatch. Science 295: 2029-2031.
38. Ruggeri, L., A.Mancusi,M. Capanni, et al. 2007. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110: 433-440.
39. Stern,M., L. Ruggeri, A. Mancusi, et al. 2008. Survival after T-cell depleted haploidentical stem cell transplantation is improved using themother as donor. Blood 112: 2990-2995.
40. Mackall,C.L., L. Granger,M.A. Sheard, et al. 1993. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 82: 2585-2594.
41. Mackall, C.L., T.A. Fleisher, M.R. Brown, et al. 1995. Age, thymopoiesis, and CD4+T-lymphocyte regeneration after intensive chemotherapy. N. Engl. J. Med. 332: 143-149.
42. Mackall, C.L., F.T. Hakim, & R.E. Gress. 1997. T-cell regeneration. All repertoires are not created equal. Immunol. Today 18: 245-251.
43. Heitger,A., N. Neu, H. Kern, et al. 1997. Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation. Blood 90: 850-857.
44. Dumont-Girard, F., E. Roux, R.A. van Lier, et al. 1998. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood 82: 4464-4471.
45. Samlowski,W.E. & C.L. Crump. 1987. Recovery of contact sensitivity responses following murine bone marrow transplantation: comparison of γ-irradiation and busulfan as preparative marrow-ablative agents. Blood 70: 1910-1920.
46. Samlowski, W.E., B.A. Araneo, M.O. Butler, et al. 1989. Peripheral lymph node T-cell recovery after syngeneic bone marrow transplantation in mice prepared with either gamma-irradiation or Busulfan. Blood 74: 1436-1445.
47. Sallusto, F.,D. Lenig, R. Forster, et al. 1999.Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
48. Szydlo,R., J.M. Goldman, J.P.Klein, et al. 1997.Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J. Clin. Oncol. 15: 1767-1777.
49. Petersdorf, E., C. Anasetti, P.J. Martin, et al. 2001. Genomics of unrelated-donor hematopoietic cell transplantation. Curr. Opin. Immunol. 13: 582-589.
50. Petersdorf, E.W., J.A. Hansen, P.J. Martin, et al. 2001. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N. Engl. J. Med. 345: 1794-1800.
51. Petersdorf, E.W., T.A. Gooley, C. Anasetti, et al. 1998. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92: 3515-3520.
52. Sasazuki, T., T. Juji, Y. Morishima, et al. 1998. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N. Engl. J. Med. 339: 1177-1185.
53. Hurley, C.K., L.A. Baxter Lowe, B. Logan, et al. 2003. NationalMarrowDonor ProgramHLA-matching guidelines for unrelated marrow transplants. Biol. BloodMarrow Transplant. 9: 610-615.
54. Saarinen-Pihkala, U.M., G. Gustafsson, O. Ringden, et al. 2001. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J. Clin. Oncol. 19: 3406-3414.
55. LaNasa,G., C. Giardini, F. Argiolu, et al. 2002.Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 99: 4350-4356.
56. Eapen, M., P. Rubinstein, M.J. Zhang, et al. 2006. Comparable long-term survival after unrelated and HLAmatched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J. Clin. Oncol. 24: 145-151.
57. Volpi, I., K. Perruccio, A. Tosti, et al. 2001. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 97: 2514-2521.
58. Guinan, E.C., V.A. Boussiotis, D. Neuberg, et al. 1999. Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. 340: 1704-1714.
59. Amrolia, P.J., G. Muccioli-Casadei, H. Huls, et al. 2006. Adoptive immunotherapy with allodepleted donor Tcells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108: 1797-1808.
60. Andrè-Schmutz, I., F. Le Deist, S. Hacein-Bey-Abina, et al. 2002. Immune reconstitutionwithout graft-versushost disease after hematopoietic stem-cell transplantation: a phase I-II study. Lancet 360: 130-137.
61. Guimond, M., A. Balassy, M. Barrette, et al. 2002. P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood 100: 375-382.
62. Mielke, S., R. Nunes, K. Rezvani, et al. 2008. A clinicalscale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111: 4392-4402.
63. Perruccio, K., F. Topini, A. Tosti, et al. 2008. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cell Mol. Dis. 40: 76-83.
64. Roy,D.C., S. Lachance, T.Kiss, et al.High doses of alloreactive T cell depleted donor lymphocytes administered post-transplant decrease infections and improve survival without severe GvHD. Blood 114: 212(a).
65. Papadopoulos, E.B.,M. Ladanyi,D. Emanuel, et al. 1994. Infusion of donor leukocytes to treat Epstein-Barr virusassociated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330: 1185-1191.
66. Rooney, C.M., C.A. Smith, C.Y. Ng, et al. 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555.
67. Walter, E.A., P.D. Greemberg, M.J. Gilbert, et al. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Eng. J. Med. 333: 1038-1044.
68. Einsele, H., E. Roosnek, N. Reifer, et al. 2002. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99: 3916-3922.
69. Comoli, P., M. Labirio, S. Basso, et al. 2002. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99: 2592-2598.
70. Perruccio, K., A. Tosti, E. Burchielli, et al. 2005. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106: 4397-4406.
71. Romani, L., F. Bistoni, R. Gaziano, et al. 2004. Thymosin {alpha} 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103: 4232-4239.
72. Romani, L., F. Bistoni, K. Perruccio, et al. 2006. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 108: 2265-2274.